Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 4/20 | 0.33 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31590279 | 0.83 | ADRB2 (0.40) | ADRB2DPP4PDE2AAKT1RPS6KA1 | |
| SCHEMBL16043564 | 0.83 | ADRB2 (0.40) | ADRB2DPP4PDE2AAKT1RPS6KA1 | |
| SCHEMBL15023130 | 0.83 | ADRB2 (0.40) | ADRB2DPP4PDE2AAKT1RPS6KA1 | |
| SCHEMBL27357109 | 0.83 | ADRB2 (0.40) | ADRB2DPP4PDE2AAKT1RPS6KA1 | |
| SCHEMBL29620491 | 0.83 | ADRB2 (0.40) | ADRB2DPP4PDE2AAKT1RPS6KA1 | |
| SCHEMBL31550151 | 0.83 | PARP1 (0.42) | PARP1VCP | |
| SCHEMBL8243510 | 0.83 | PARP1 (0.42) | PARP1VCP | |
| SCHEMBL4444491 | 0.81 | PARP1 (0.41) | ADRB2PARP1DPP4AKT1PFKFB3 | |
| SCHEMBL248016 | 0.80 | PARP1 (0.40) | ADRB2PARP1DPP4PFKFB3VCP | |
| SCHEMBL30726196 | 0.80 | PARP1 (0.40) | ADRB2PARP1DPP4PFKFB3VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4466071-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | Redx Pharma Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632845-A | Modulators of Rho-associated protein kinase (ROCK) | 莱德克斯制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2017201683-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| EP-1222178-A1 | ALKYL-AMINO-1,3,5-TRIAZINES AND THEIR USE AS HERBICIDES | Aventis CropScience GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001027093-A1 | ALKYL-AMINO-1,3,5-TRIAZINES AND THEIR USE AS HERBICIDES | AVENTIS CROPSCIENCE GMBH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | ADRB2 2515/4885PARP1 1526/4885DPP4 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.